Cost effectiveness of hepatitis C direct acting agents
Authors:
Open Access
- 3 May 2024
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 24 (5) , 589-597
Abstract
Introduction of direct acting antivirals (DAA) has transformed treatment of chronic hepatitis C (HCV) and made elimination of HCV an achievable goal set forward by World Health Organization by 2030. Multiple barriers need to be overcome for successful eradication of HCV. Availability of pan-genotypic HCV regimens has decreased the need for genotype testing, but maintained high efficacy associated with DAAs. In this review, we will assess the cost-effectiveness of DAA treatment in patients with chronic HCV disease, with emphasis on general, cirrhosis, and vulnerable populations. Multiple barriers exist limiting eradication of HCV, including cost to treatment, access, simplified testing, and implementing policy to foster treatment for all groups of HCV patients. Clinically, DAAs have drastically changed the landscape of HCV, but focused targeting of vulnerable groups is needed. Public policy will continue to play a strong role in eliminating HCV. While we will focus on the cost-effectiveness of DAA, several other factors regarding HCV require on going attention, such as increasing public awareness and decreasing social stigma associated with HCV, offering universal screening followed by linkage to treatment and improving preventive interventions to decrease spread of HCV.Keywords
This publication has 61 references indexed in Scilit:
- HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta‐analysisHepatology, 2022
- Cost-effectiveness of Universal and Targeted Hepatitis C Virus Screening in the United StatesJAMA Network Open, 2020
- Value-Based Pricing and Patient Access for Specialty DrugsJAMA, 2018
- Toward the elimination of hepatitis C in the United StatesHepatology, 2018
- Is increased hepatitis C virus case‐finding combined with current or 8‐week to 12‐week direct‐acting antiviral therapy cost‐effective in UK prisons? A prevention benefit analysisHepatology, 2016
- Toward a more accurate estimate of the prevalence of hepatitis C in the United StatesHepatology, 2015
- Cost‐effectiveness of hepatitis C treatment for patients in early stages of liver diseaseHepatology, 2015
- Treatment of Hepatitis CJAMA, 2014
- Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infectionHepatology, 2012
- Recommendations of the Panel on Cost-Effectiveness in Health and MedicineJAMA, 1996